Agalsidase beta
Therapeutic Indications
Agalsidase beta is indicated for:
Fabry Disease
Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)
Agalsidase beta is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 1 mg/kg body weight once every 2 weeks
Fabry Disease
Irrespective of gender only Adults (18 - 65 years old)
Agalsidase beta is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency). 2
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 1 mg/kg body weight once every 2 weeks
Contraindications
Active ingredient Agalsidase beta is contraindicated in the following cases:
Chloroquine
No gender/age discrimination
Agalsidase beta should not be co-administered with chloroquine since this substance has the potential to inhibit intra-cellular α-galactosidase activity.